Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'". (2018)
Attributed to:
Nottingham Molecular Pathology Node (NMPN) for Integrated Multi-platform Biomarker Research and Knowledge Transfer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2017.11.044
PubMed Identifier: 29339112
Publication URI: http://europepmc.org/abstract/MED/29339112
Type: Journal Article/Review
Volume: 68
Parent Publication: Journal of hepatology
Issue: 4
ISSN: 0168-8278